The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

scientific article published on 19 February 2013

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1028031188
P356DOI10.1186/2162-3619-2-5
P932PMC publication ID3585848
P698PubMed publication ID23422286
P5875ResearchGate publication ID235668733

P2093author name stringNeil Hawkins
Stuart Mealing
Catherine Davis
James Clark
Ishan Hirji
Leticia Barcena
Victoria Eaton
P2860cites workSurvival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trialsQ58179557
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trialsQ83981223
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaQ84823041
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaQ29614280
Combination of direct and indirect evidence in mixed treatment comparisonsQ29619499
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiQ30357011
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaQ33393383
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant dataQ33436401
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.Q33886162
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysisQ33979738
Simultaneous comparison of multiple treatments: combining direct and indirect evidence.Q34081552
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaQ34183674
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaQ34620246
Bayesian methods for evidence synthesis in cost-effectiveness analysisQ36381197
Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviewsQ37433313
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.Q37888895
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaQ43043759
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaQ43899710
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experienceQ44045908
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyQ44912433
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaQ46090252
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.Q46419894
P275copyright licenseCreative Commons Attribution 2.0 GenericQ19125117
P6216copyright statuscopyrightedQ50423863
P433issue1
P921main subjectimatinibQ177094
dasatinibQ419940
chronic myeloid leukemiaQ729735
dasatinib monohydrateQ27139135
P304page(s)5
P577publication date2013-02-19
P1433published inExperimental Hematology & OncologyQ23979095
P1476titleThe relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
P478volume2

Reverse relations

cites work (P2860)
Q28649477A polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathway
Q93092100BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Q36290275Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib
Q38936993First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis
Q33794548Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
Q58859336How low can you go? A current perspective on low-abundance proteomics
Q41575103Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.
Q35225342Successful nilotinib treatment in a child with chronic myeloid leukemia
Q38748512Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

Search more.